奥博资本（OrbiMed）推出5.51亿美元亚洲私募股权基金

• OrbiMed在中国、印度生物科技行业的投资增加了5.51亿美元
  

您想要更多的亚洲生物科技行业蓬勃发展的证据吗？ OrbiMed（奥博资本）可以提供。

作为世界著名的风险投资公司，奥博资本于2017年9月5日宣布，其第三家以亚洲为主的私募股权基金募集了高达5.51亿美元，远高于上次的3.25亿美元。

OrbiMed普通合伙人Carter Neild先生表示：“这个新的更大的基金反映了我们对中国和印度的投资机会的热情，其医疗保健市场增长率远远优于大多数发达国家。”

资深董事总经理王健博士和王国玮博士领导奥博上海办事处，而资深董事总经理Sunny Sharma博士则在孟买掌舵。

这笔新进的现金将成为15至20家医疗保健、生物科技和诊断公司取得成功的关键，这些公司可望获得奥博全球集团的支持。OrbiMed预计每一家生物技术公司将可能获得本基金1000万到7500万美元的投资。

欢迎欣赏公司发布的新闻稿！

OrbiMed Launches $551 Million Asia Private Equity Fund

September 05, 2017 08:00 AM Eastern Daylight Time

NEW YORK--(BUSINESS WIRE)--OrbiMed, a leading investment firm focused on the healthcare sector, announced the closing of its third Asia-focused private equity fund, OrbiMed Asia Partners III, LP, with approximately $551 million in capital commitments.

Consistent with its predecessor funds, Asia Partners III will invest broadly across the Asian healthcare industry, with a focus on growth stage product- and services-oriented companies in China and India. The Fund will target investments from $10 million to $75 million per company across 15 to 20 opportunities. Where appropriate, Asia Partners III may co-invest with OrbiMed’s global team, enabling substantially larger investments and leveraging the full financial and strategic resources of OrbiMed’s 100+ team members and $14 billion global investment platform.

“This new, larger fund reflects our enthusiasm for the investment opportunities in China and India, which have healthcare market growth rates far superior to most developed countries,” noted Carter Neild, an OrbiMed General Partner.

“With over half of the world’s patient population, the demand for quality healthcare in Asia still greatly exceeds supply,” said Jonathan Wang, a Senior Managing Director. “China’s healthcare market is not only growing rapidly, but also becoming a leading center of innovation, and is increasingly integrated with the rest of the world, especially the U.S.”

“With India still spending less than 5% of its GDP on healthcare and boasting the fastest growth rate of all major economies, we see compelling opportunities for investments across healthcare services, pharmaceuticals, and diagnostics,” observed Senior Managing Director Dr. Sunny Sharma, who leads OrbiMed’s team in India.

“OrbiMed now has over $2 billion invested in Asian healthcare companies, positioning our team as a strong partner for entrepreneurs, institutions and companies seeking to shape the future of Asia’s healthcare markets,” commented Dr. David Wang, a Senior Managing Director.

OrbiMed’s Shanghai office was opened in 2007 and is led by Dr. Jonathan Wang and Dr. David Wang. OrbiMed’s Mumbai office was opened in 2008 and is led by Dr. Sunny Sharma.

About OrbiMed

OrbiMed is a leading healthcare investment firm, with over $14 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, utilizing a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed maintains offices in New York City, San Francisco, Shanghai, Mumbai and Herzliya. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and global team resources and support to help build world-class healthcare companies.

Contacts

OrbiMed
W. Carter Neild, CFA, 212-739-6400
[e-mail]
www.OrbiMed.com

备注：药时代本着推荐、分享有价值的信息的宗旨，进行编译。因水平有限，不当、错误之处难免，我们对译文的质量负全部的责任，热烈欢迎朋友、老师们的批评指正！

参考资料及重要声明：

* OrbiMed lines up $551M gamble on China, India biotech sectors（作者： arsalan arif，发表时间：2017年9月5日）；

* OrbiMed Launches $551 Million Asia Private Equity Fund （来源：BusinessWire，发表时间：2017年9月5日）

图片来源：原文、公司官网、Google，等。

所有版权归拥有者！

药时代编译，旨在分享有价值的信息，仅供个人学习参考。欢迎阅读原文，对译文批评指正！衷心感谢！

—— 欢迎阅读近3个月内10,000+文章！——

欢迎联系我们！[e-mail]